Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 2/20 | 0.41 |
| ▸ | KDM1B | Q8NB78 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | PPOX | P50336 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.37 |
| ▸ | HTR2C | P28335 | 2/20 | 0.37 |
| ▸ | HTR2B | P41595 | 2/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1223997 | 0.92 | NPC1 (0.45) | GAANPC1TAAR1KDM1AKDM1B | |
| SCHEMBL31118436 | 0.92 | NPC1 (0.45) | GAANPC1TAAR1KDM1AKDM1B | |
| SCHEMBL4148256 | 0.83 | HTR2A (0.44) | GAANPC1TAAR1POLBPTGS1 | |
| SCHEMBL31566995 | 0.83 | HTR2A (0.44) | GAANPC1TAAR1POLBPTGS1 | |
| SCHEMBL30888547 | 0.82 | POLB (0.54) | GAANPC1TAAR1POLBNPSR1 | |
| SCHEMBL4573417 | 0.82 | PRKDC (0.48) | TAAR1POLBNPSR1PTGS2L3MBTL1 | |
| SCHEMBL31085113 | 0.82 | PRKDC (0.48) | TAAR1POLBNPSR1PTGS2L3MBTL1 | |
| SCHEMBL2125933 | 0.80 | GAA (0.50) | GAANPC1TAAR1POLBNPSR1 | |
| SCHEMBL435716 | 0.80 | POLB (0.41) | TAAR1KDM1AKDM1BPOLBNPSR1 | |
| SCHEMBL30745361 | 0.80 | POLB (0.41) | TAAR1KDM1AKDM1BPOLBNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-12522619-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| WO-2025049820-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| EP-4463462-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | Annexon, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| CN-118715231-A | Complement factor inhibitors and uses thereof | 安尼艾克松股份有限公司 | 2024-09-27 | — | — | CN | disclosed |
| WO-2024030651-A1 | GPX4 INHIBITORS AND USE THEREOF | SONATA THERAPEUTICS, INC. (US) | 2024-02-08 | — | — | WO | disclosed |
| US-20230265109-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230265109-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230265109-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2023-08-24 | — | — | US | disclosed |
| WO-2023137166-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. (US) | 2023-07-20 | — | — | WO | disclosed |
| WO-2023137166-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. (US) | 2023-07-20 | — | — | WO | disclosed |
| EP-1844026-B1 | MORPHOLINES AS 5HT2C AGONISTS | HOFFMANN LA ROCHE (CH) | 2011-04-27 | — | — | EP | disclosed |
| US-7323466-B2 | Morpholine derivatives as 5HT2C receptor agonists for the treatment of obesity | HOFFMAN-LA ROCHE INC. (US) | 2008-01-29 | — | — | US | disclosed |
| EP-1844026-A2 | MORPHOLINES AS 5HT2C AGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-10-17 | — | — | EP | disclosed |
| US-20060178510-A1 | New morpholine derivatives as 5HT2C receptor agonists for the treatment of obesity | HOFFMANN-LA ROCHE INC. | 2006-08-10 | — | — | US | disclosed |
| WO-2006077025-A2 | MORPHOLINES AS 5HT2C AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | STAT6, NCOR2, NCOR1 | GAA 4235/4885NPC1 1390/4885TAAR1 517/4885 |
| US-20060178510-A1 | New morpholine derivatives as 5HT2C receptor agonists for the treatment of obesity | HTR2C, HTR1A, HTR1B | GAA 2344/4885NPC1 1094/4885TAAR1 45/4885 |
| US-20230265109-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFB, CFH, C9 | GAA 233/4885NPC1 460/4885TAAR1 3883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.